ANIP - ANI Pharmaceuticals Inc Stock Price, Fair Value and News

65.43USD-0.71 (-1.07%)Market Closed

Market Summary

USD65.43-0.71

Market Closed

-1.07%

ANIP Alerts

2 major insider sales recently.

ANIP Stock Price

View Fullscreen

ANIP RSI Chart

ANIP Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

62.72

Price/Sales (Trailing)

2.42

EV/EBITDA

11.18

Price/Free Cashflow

10.7

ANIP Price/Sales (Trailing)

ANIP Profitability

Operating Margin

82.47%

EBT Margin

4.08%

Return on Equity

4.34%

Return on Assets

2.08%

Free Cashflow Yield

9.35%

ANIP Fundamentals

ANIP Revenue

Revenue (TTM)

486.8M

Rev. Growth (Yr)

39.71%

Rev. Growth (Qtr)

-0.13%

ANIP Earnings

Earnings (TTM)

18.8M

Earnings Growth (Yr)

127.22%

Earnings Growth (Qtr)

-88.38%

Breaking Down ANIP Revenue

Last 7 days

0.9%

Last 30 days

-4.9%

Last 90 days

19.8%

Trailing 12 Months

70.9%

How does ANIP drawdown profile look like?

ANIP Financial Health

Current Ratio

3.57

Debt/Equity

0.66

Debt/Cashflow

0.42

ANIP Investor Care

Shares Dilution (1Y)

10.71%

Diluted EPS (TTM)

0.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	358.7M	401.4M	449.4M	486.8M
2022	226.1M	251.3M	283.1M	316.4M
2021	213.2M	213.4M	212.5M	216.1M
2020	203.4M	197.5M	199.2M	208.5M
2019	208.0M	215.1M	215.7M	206.5M
2018	186.7M	189.2M	191.7M	201.6M
2017	144.7M	158.1M	167.8M	176.8M
2016	78.1M	89.9M	108.5M	128.6M
2015	63.9M	76.7M	79.3M	76.3M
2014	35.4M	35.9M	45.5M	56.0M
2013	17.8M	18.7M	21.5M	30.1M
2012	5.4M	10.4M	15.4M	20.4M
2011	2.0M	1.5M	944.9K	435.2K
2010	1.6M	1.9M	2.2M	2.5M
2009	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ANI Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	shanmugam muthusamy	sold	-1,095,440	65.17	-16,809	head of r&d, coo-novitium ops
Apr 18, 2024	shanmugam muthusamy	sold	-677,287	64.98	-10,423	head of r&d, coo-novitium ops
Apr 17, 2024	shanmugam muthusamy	sold	-622,608	65.4	-9,520	head of r&d, coo-novitium ops
Apr 16, 2024	shanmugam muthusamy	sold	-386,211	66.2	-5,834	head of r&d, coo-novitium ops
Apr 15, 2024	shanmugam muthusamy	sold	-491,771	66.33	-7,414	head of r&d, coo-novitium ops
Apr 12, 2024	cook meredith	sold	-16,947	67.79	-250	sr. vp, general counsel & sec.
Apr 10, 2024	marken james g.	sold (taxes)	-187,421	66.96	-2,799	svp ops & prod dev
Apr 10, 2024	carey stephen p.	sold (taxes)	-303,597	66.96	-4,534	svp & cfo
Apr 01, 2024	gassert chad	sold	-1,345,000	67.25	-20,000	svp - corp. dev. & strategy
Mar 23, 2024	carey stephen p.	sold (taxes)	-432,092	69.58	-6,210	svp & cfo

Which funds bought or sold ANIP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	reduced	-0.13	902,285	4,481,970	0.26%
Apr 23, 2024	Louisiana State Employees Retirement System	unchanged	-	104,925	518,475	0.01%
Apr 23, 2024	FIFTH THIRD BANCORP	new	-	138	138	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-22.4	-10,000	329,000	-%
Apr 23, 2024	WEDGE CAPITAL MANAGEMENT L L P/NC	added	23.39	1,976,540	5,589,920	0.09%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	515,433	515,433	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-22,414	423,255	-%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	55,804	357,916	0.01%
Apr 19, 2024	State of Alaska, Department of Revenue	reduced	-7.49	87,000	634,000	0.01%
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	unchanged	-	48,545	266,980	1.33%

Are Funds Buying or Selling ANIP?

Are funds buying ANIP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANIP

No. of Funds

ANIP Alerts

2 major insider sales recently.

Unveiling ANI Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 14, 2024	meridian venture partners ii gp, l.p.	6.7%	1,419,381	SC 13D/A
Feb 13, 2024	vanguard group inc	6.31%	1,288,972	SC 13G
Feb 12, 2024	rubric capital management lp	5.51%	1,125,000	SC 13G
Jan 23, 2024	blackrock inc.	12.4%	2,524,660	SC 13G/A
Jan 17, 2024	esjay llc	4.6%	932,620	SC 13D/A
Dec 18, 2023	meridian venture partners ii gp, l.p.	8.1%	1,644,381	SC 13D/A
Dec 05, 2023	esjay llc	4.8%	982,620	SC 13D/A
Aug 18, 2023	meridian venture partners ii gp, l.p.	9.0%	1,819,259	SC 13D/A
Jan 26, 2023	blackrock inc.	11.4%	1,983,237	SC 13G/A
Jan 20, 2023	blackrock inc.	11.4%	1,983,237	SC 13G/A

Recent SEC filings of ANI Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	4	Insider Trading
Apr 19, 2024	144	Notice of Insider Sale Intent
Apr 18, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	8-K	Current Report
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 15, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading

Peers (Alternatives to ANI Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-3.67%	-8.64%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	2.46%	9.45%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-3.80%	-34.05%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-0.95%	11.90%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.68%	-22.69%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-6.26%	55.93%	-25.3	0.92	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-2.65%	-15.52%	-325.34	0.89	4.58%	90.97%
ALKS	4.1B	1.7B	-11.07%	-16.83%	11.58	2.48	49.61%	324.78%
BHC	3.1B	8.8B	-10.77%	12.83%	-5.27	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.43%	-0.05%	14.34	3.06	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-20.35%	-21.70%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-17.90%	-49.19%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-14.29%	38.83%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-32.73%	-94.43%	-0.18	0.13	80.00%	43.08%
ACOR	645.9K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

ANI Pharmaceuticals Inc News

Latest updates

ANI Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-0.1%	132	132	117	107	94.00	84.00	74.00	64.00	61.00	52.00	49.00	55.00	57.00	53.00	48.00	50.00	48.00	51.00	54.00	53.00	57.00
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	20.00	25.00	20.00	21.00	22.00	18.00	15.00	16.00	15.00	20.00
Costs and Expenses	9.7%	125	114	104	97.00	92.00	89.00	87.00	84.00	85.00	56.00	64.00	51.00	57.00	50.00	60.00	58.00	53.00	44.00	45.00	48.00	46.00
S&GA Expenses	5.8%	44.00	42.00	39.00	36.00	33.00	30.00	32.00	29.00	31.00	17.00	19.00	18.00	14.00	16.00	21.00	14.00	14.00	14.00	14.00	13.00	13.00
R&D Expenses	-11.3%	10.00	11.00	7.00	6.00	5.00	8.00	4.00	5.00	3.00	2.00	3.00	3.00	4.00	3.00	3.00	6.00	5.00	5.00	6.00	4.00	3.00
EBITDA Margin	-0.6%	0.23*	0.23*	0.18*	0.12*	0.05*	-0.05*	-0.05*	-0.08*	0.00*	0.12*	0.15*	0.17*	0.12*	0.10*	0.11*	0.19*	0.26*	0.32*	0.32*	0.32*	0.30*
Interest Expenses	0.4%	8.00	8.00	11.00	4.00	7.00	3.00	6.00	6.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	0.00	3.00
Income Taxes	-112.3%	-0.19	2.00	-1.00	1.00	-1.47	-3.62	-3.90	-5.77	-6.72	-2.68	-4.04	-0.01	1.00	-0.37	-1.40	-2.90	-2.82	0.00	-0.65	0.00	2.00
Earnings Before Taxes	-91.8%	1.00	12.00	5.00	2.00	-5.73	-12.22	-18.82	-25.90	-30.85	-7.13	-18.15	0.00	-2.37	0.00	-13.80	-9.86	-7.66	4.00	6.00	1.00	7.00
EBT Margin	39.0%	0.04*	0.03*	-0.03*	-0.10*	-0.20*	-0.31*	-0.33*	-0.36*	-0.26*	-0.13*	-0.10*	-0.08*	-0.12*	-0.16*	-0.14*	-0.04*	0.02*	0.08*	0.10*	0.09*	0.10*
Net Income	-88.4%	1.00	10.00	6.00	1.00	-4.24	-8.60	-14.92	-20.13	-24.14	-4.45	-14.11	0.00	-3.63	0.00	-12.34	-7.01	-4.83	4.00	7.00	0.00	5.00
Net Income Margin	29.6%	0.04*	0.03*	-0.01*	-0.07*	-0.15*	-0.24*	-0.25*	-0.28*	-0.20*	-0.10*	-0.08*	-0.07*	-0.11*	-0.12*	-0.10*	-0.01*	0.03*	0.08*	0.08*	0.07*	0.08*
Free Cashflow	39.5%	42.00	30.00	18.00	19.00	-7.54	1.00	-12.80	-20.89	-12.54	-5.97	-0.69	20.00	-7.82	-3.37	20.00	0.00	3.00	20.00	3.00	13.00	26.00

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.6%	904	890	859	765	760	739	751	745	772	470	480	464	461	463	465	482	457	457	447	434	431
Current Assets	4.5%	520	497	459	365	344	309	322	301	322	191	192	183	170	166	157	159	188	182	169	152	153
Cash Equivalents	14.5%	221	193	162	68.00	48.00	56.00	63.00	77.00	100	15.00	24.00	25.00	8.00	18.00	28.00	20.00	62.00	60.00	41.00	38.00	43.00
Inventory	4.3%	111	107	104	104	105	96.00	93.00	83.00	82.00	62.00	68.00	60.00	61.00	59.00	53.00	53.00	48.00	46.00	45.00	42.00	41.00
Net PPE	0.9%	45.00	44.00	44.00	43.00	43.00	43.00	44.00	53.00	53.00	40.00	40.00	41.00	41.00	40.00	40.00	40.00	41.00	40.00	39.00	38.00	38.00
Goodwill	0%	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	2.00
Liabilities	2.7%	447	435	425	426	422	402	414	399	413	279	288	260	265	267	274	281	244	244	239	235	233
Current Liabilities	8.3%	145	134	123	126	99.00	82.00	96.00	80.00	88.00	85.00	89.00	83.00	79.00	76.00	79.00	79.00	62.00	171	167	165	166
Long Term Debt	-0.1%	285	285	285	285	286	286	286	286	287	186	190	169	172	175	178	188	176	65.00	66.00	67.00	67.00
LT Debt, Current	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	16.00	15.00	14.00	13.00	13.00	12.00	12.00	10.00	4.00	4.00	3.00	3.00
LT Debt, Non Current	-0.1%	285	285	285	285	286	286	286	286	287	186	190	169	172	175	178	188	176	65.00	66.00	67.00	67.00
Shareholder's Equity	0.7%	433	430	495	408	314	399	395	321	388	191	192	204	0.00	195	191	201	213	213	208	200	197
Retained Earnings	0.9%	-80.13	-80.88	-90.41	-96.25	-97.29	-92.60	-83.63	-68.30	-47.76	-23.44	-18.99	-4.89	-4.97	-1.34	-1.77	11.00	18.00	22.00	19.00	12.00	11.00
Additional Paid-In Capital	1.5%	514	507	495	408	404	399	395	391	388	222	219	216	214	212	209	204	201	197	195	190	187
Accumulated Depreciation	-	-	-	-	27.00	33.00	30.00	27.00	25.00	23.00	21.00	20.00	19.00	18.00	-	-	-	-	-	-	-	-
Shares Outstanding	1.9%	18.00	18.00	17.00	16.00	16.00	16.00	16.00	16.00	13.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Float	-	-	-	824	-	-	-	373	-	-	-	348	-	-	-	316	-	-	-	658	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	39.1%	44,740	32,169	20,626	21,424	-4,400	3,623	-11,484	-18,942	-12,185	-5,402	241	20,668	-5,709	-1,614	20,880	1,710	4,803	21,793	4,744	14,291	27,232
Share Based Compensation	3.3%	5,621	5,444	5,249	4,338	3,737	3,869	3,756	3,237	2,968	2,808	2,844	1,869	2,393	2,383	5,736	2,424	2,444	2,470	2,593	1,710	1,828
Cashflow From Investing	-5.0%	-4,779	-4,553	-6,826	-2,353	-3,142	-9,814	-604	-2,178	-82,213	-583	-21,950	-737	-2,119	-5,809	-2,848	-57,546	-1,374	-1,932	-3,958	-20,285	-407
Cashflow From Financing	-417.4%	-11,918	3,755	80,150	-4,548	-508	-911	-1,437	-2,270	179,444	-3,022	20,898	-2,725	-2,208	-2,378	-10,744	13,891	-766	-770	1,580	1,206	-27,946
Dividend Payments	0%	406	406	407	406	407	406	407	405	190	-	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	-65.5%	231	670	537	3,549	119	239	483	1,118	1.00	73.00	468	348	-	-	-	-	-	-	-	-	-

ANIP Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net Revenues	$ 486,816,000	$ 316,385,000	$ 216,136,000
Operating Expenses
Cost of sales (excluding depreciation and amortization)	181,513,000	138,785,000	100,610,000
Research and development	34,286,000	22,318,000	11,369,000
Selling, general, and administrative	161,697,000	124,044,000	84,294,000
Depreciation and amortization	59,791,000	56,972,000	47,252,000
Contingent consideration fair value adjustment	1,426,000	3,758,000	500,000
Legal settlement expense	0	0	8,750,000
Purified Cortrophin Gel pre-launch charges	0	0	780,000
Restructuring activities	1,132,000	5,679,000	0
Intangible asset impairment charge	0	112,000	2,374,000
Total Operating Expenses	439,845,000	351,668,000	255,929,000
Operating Income (Loss)	46,971,000	(35,283,000)	(39,793,000)
Other Expense, net
Interest expense, net	(26,940,000)	(28,052,000)	(11,922,000)
Other (expense) income, net	(159,000)	670,000	(4,343,000)
Income (Loss) Before Expense (Benefit) for Income Taxes	19,872,000	(62,665,000)	(56,058,000)
Income tax expense (benefit)	1,093,000	(14,769,000)	(13,455,000)
Net Income (Loss)	18,779,000	(47,896,000)	(42,603,000)
Dividends on Series A Convertible Preferred Stock	(1,625,000)	(1,625,000)	(190,000)
Net Loss Available to Common Shareholders	$ 17,154,000	$ (49,521,000)	$ (42,793,000)
Basic and Diluted Income (Loss) Per Share:
Basic Income (Loss) Per Share (in dollars per share)	$ 0.86	$ (3.05)	$ (3.40)
Diluted Income (Loss) Per Share (in dollars per share)	$ 0.85	$ (3.05)	$ (3.40)
Basic Weighted-Average Shares Outstanding (in shares)	18,001	16,260	12,596
Diluted Weighted-Average Shares Outstanding (in shares)	18,194	16,260	12,596

ANIP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 221,121	$ 48,228
Current restricted cash	0	5,006
Accounts receivable, net of $97,262 and $161,052 of adjustments for chargebacks and other allowances at December 31, 2023 and 2022, respectively	162,079	165,438
Inventories	111,196	105,355
Prepaid income taxes	0	3,827
Assets held for sale	8,020	8,020
Prepaid expenses and other current assets	17,400	8,387
Total Current Assets	519,816	344,261
Non-current Assets
Property and equipment, net	44,593	43,246
Deferred tax assets, net of deferred tax liabilities and valuation allowance	90,711	81,363
Intangible assets, net	209,009	251,635
Goodwill	28,221	28,221
Derivatives and other non-current assets	12,072	11,361
Total Assets	904,422	760,087
Current Liabilities
Current debt, net of deferred financing costs	850	850
Accounts payable	36,683	29,305
Accrued royalties	16,276	9,307
Accrued compensation and related expenses	23,786	10,312
Accrued government rebates	12,168	10,872
Income taxes payable	8,164	0
Returned goods reserve	29,678	33,399
Current contingent consideration	12,266	0
Accrued expenses and other	5,606	5,394
Total Current Liabilities	145,477	99,439
Non-current Liabilities
Non-current debt, net of deferred financing costs and current component	284,819	285,669
Non-current contingent consideration, net of current	11,718	35,058
Other non-current liabilities	4,809	1,381
Total Liabilities	446,823	421,547
Commitments and Contingencies (Note 15)
Mezzanine Equity
Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at December 31, 2023 and 2022	24,850	24,850
Stockholders’ Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 20,730,896 shares issued and 20,466,953 outstanding at December 31, 2023; 17,643,497 shares issued and 17,494,466 shares outstanding at December 31, 2022	2	1
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December 31, 2023 and 2022 respectively	0	0
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December 31, 2023 and 2022, respectively	0	0
Treasury stock, 263,943 shares of common stock, at cost, at December 31, 2023 and 149,031 shares of common stock, at cost, at December 31, 2022	(10,081)	(5,094)
Additional paid-in capital	514,103	403,901
Accumulated deficit	(80,132)	(97,286)
Accumulated other comprehensive income, net of tax	8,857	12,168
Total Stockholders’ Equity	432,749	313,690
Total Liabilities, Mezzanine Equity, and Stockholders’ Equity	$ 904,422	$ 760,087

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

CEO	Mr. Nikhil Lalwani
WEBSITE	anipharmaceuticals.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	600

ANI Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ANI Pharmaceuticals Inc? What does ANIP stand for in stocks?

ANIP is the stock ticker symbol of ANI Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ANI Pharmaceuticals Inc (ANIP)?

As of Tue Apr 23 2024, market cap of ANI Pharmaceuticals Inc is 1.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIP stock?

You can check ANIP's fair value in chart for subscribers.

What is the fair value of ANIP stock?

You can check ANIP's fair value in chart for subscribers. The fair value of ANI Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ANI Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ANI Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ANIP is over valued or under valued. Whether ANI Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ANI Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIP.

What is ANI Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ANIP's PE ratio (Price to Earnings) is 63.4 and Price to Sales (PS) ratio is 2.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ANI Pharmaceuticals Inc's stock?

In the past 10 years, ANI Pharmaceuticals Inc has provided 0.078 (multiply by 100 for percentage) rate of return.